8RYN image
Entry Detail
PDB ID:
8RYN
Keywords:
Title:
Structure of S2 TCR in complex with HLA-A*11:01 bound to ELFSYLIEK peptide
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2024-02-09
Release Date:
2024-09-04
Method Details:
Experimental Method:
Resolution:
1.97 Å
R-Value Free:
0.25
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:MHC class I antigen
Chain IDs:A
Chain Length:276
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Beta-2-microglobulin
Chain IDs:B
Chain Length:100
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:ELFSYLIEK peptide
Chain IDs:C
Chain Length:9
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:TCR alpha
Chain IDs:D
Chain Length:198
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:TCR beta
Chain IDs:E
Chain Length:245
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Broadening alloselectivity of T cell receptors by structure guided engineering.
Sci Rep 14 26851 26851 (2024)
PMID: 39500929 DOI: 10.1038/s41598-024-75140-7

Abstact

Specificity of a T cell receptor (TCR) is determined by the combination of its interactions to the peptide and human leukocyte antigen (HLA). TCR-based therapeutic molecules have to date targeted a single peptide in the context of a single HLA allele. Some peptides are presented on multiple HLA alleles, and by engineering TCRs for specific recognition of more than one allele, there is potential to expand the targetable patient population. Here, as a proof of concept, we studied two TCRs, S2 and S8, binding to the PRAME peptide antigen (ELFSYLIEK) presented by HLA alleles HLA-A*03:01 and HLA-A*11:01. By structure-guided affinity maturation targeting a specific residue on the HLA surface, we show that the affinity of the TCR can be modulated for different alleles. Using a combination of affinity maturation and functional T cell assay, we demonstrate that an engineered TCR can target the same peptide on two different HLA alleles with similar affinity and potency. This work highlights the importance of engineering alloselectivity for designing TCR based therapeutics suitable for differing global populations.

Legend

Protein

Chemical

Disease

Primary Citation of related structures